Mylan's 3rd Circ. Doryx Loss A Hurdle To Product-Hop Suits

By Eric Kroh (May 10, 2017, 2:19 PM EDT) -- Mylan won't appeal an adverse Third Circuit ruling in an antitrust suit over acne treatment Doryx — and though the decision does not preclude product-hopping claims, it could make it harder for them to succeed, such as in the Suboxone case brought by more than 40 states in the same circuit....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!